2:15 PM - 2:30 PM
Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
Richard D. Carvajal, MD
2:30 PM - 2:45 PM
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma.
Mark R. Middleton, PhD, FRCP
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.
Avinash Gupta, MBBS BSc MRCP
SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy.
Vincent M. Chung, MD
The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
Howard S. Hochster, MD
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
Corey A. Carter, MD
Poster Board: #15
Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
Andrew H. Ko, MD
Poster Board: #6
Dcaf7 just wanted to say thanks for all the DD you have done for arry investors. I emailed IR and asked them if they would be presenting at ASCO 2013 they returned an email saying they would not be there. have you heard different ?